It's our new normal!_老虎社区_美港股上老虎

BengGhee
2021-08-12

It's our new normal!

BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster<blockquote>BioNTech和Moderna因FDA可能批准增强剂的报道而上涨</blockquote>

BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo

BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster<blockquote>BioNTech和Moderna因FDA可能批准增强剂的报道而上涨</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":894093007,"tweetId":"894093007","gmtCreate":1628776703809,"gmtModify":1633689588263,"author":{"id":3573448700377086,"idStr":"3573448700377086","authorId":3573448700377086,"authorIdStr":"3573448700377086","name":"BengGhee","avatar":"https://static.tigerbbs.com/e5daa49018a4a9f082bff4985c6a12e9","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>It's our new normal!</p></body></html>","htmlText":"<html><head></head><body><p>It's our new normal!</p></body></html>","text":"It's our new normal!","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/894093007","repostId":2158325931,"repostType":4,"repost":{"id":"2158325931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628776169,"share":"https://www.laohu8.com/m/news/2158325931?lang=zh_CN&edition=full","pubTime":"2021-08-12 21:49","market":"us","language":"en","title":"BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster<blockquote>BioNTech和Moderna因FDA可能批准增强剂的报道而上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2158325931","media":"Tiger Newspress","summary":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p><p><blockquote>BioNTech和Moderna股价周四早盘上涨，有望收复前一交易日的部分跌幅，此前《华尔街日报》报道称FDA可能授权为免疫功能低下的人注射Covid-19加强针。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p><p><blockquote>BioNTech和Moderna在前一交易日分别暴跌14%和15.6%后上涨3.96%和2%。辉瑞(NYSE：PFE)周三下跌4%，现上涨1%。</blockquote></p><p> The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p><p><blockquote>《华尔街日报》报道称，由于德尔塔变异毒株的快速传播，新冠病例激增，美国食品和药物管理局即将决定授权为免疫力较弱的人进行加强注射。</blockquote></p><p> There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p><p><blockquote>越来越多的证据表明，对于免疫力低下的人来说，两针疫苗是不够的。疫苗制造商计划在本月或下个月向FDA申请加强注射的批准。</blockquote></p><p> BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p><p><blockquote>BioNTech、Moderna和辉瑞周三均收低，此前有消息称，欧洲药品监管机构正在研究少数人在接种Covid-19疫苗后报告的三种新病症，以评估它们是否可能是副作用。</blockquote></p><p> The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p><p><blockquote>据报道，服用Moderna或BioNTech-Pfizer生产的mRNA疫苗的患者出现了这种情况。</blockquote></p><p> Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p><p><blockquote>辉瑞和BioNTech正在合作研究和营销他们的新冠肺炎疫苗。疫苗的费用和利润由辉瑞和BioNTech平分。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster<blockquote>BioNTech和Moderna因FDA可能批准增强剂的报道而上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster<blockquote>BioNTech和Moderna因FDA可能批准增强剂的报道而上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-12 21:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p><p><blockquote>BioNTech和Moderna股价周四早盘上涨，有望收复前一交易日的部分跌幅，此前《华尔街日报》报道称FDA可能授权为免疫功能低下的人注射Covid-19加强针。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p><p><blockquote>BioNTech和Moderna在前一交易日分别暴跌14%和15.6%后上涨3.96%和2%。辉瑞(NYSE：PFE)周三下跌4%，现上涨1%。</blockquote></p><p> The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p><p><blockquote>《华尔街日报》报道称，由于德尔塔变异毒株的快速传播，新冠病例激增，美国食品和药物管理局即将决定授权为免疫力较弱的人进行加强注射。</blockquote></p><p> There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p><p><blockquote>越来越多的证据表明，对于免疫力低下的人来说，两针疫苗是不够的。疫苗制造商计划在本月或下个月向FDA申请加强注射的批准。</blockquote></p><p> BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p><p><blockquote>BioNTech、Moderna和辉瑞周三均收低，此前有消息称，欧洲药品监管机构正在研究少数人在接种Covid-19疫苗后报告的三种新病症，以评估它们是否可能是副作用。</blockquote></p><p> The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p><p><blockquote>据报道，服用Moderna或BioNTech-Pfizer生产的mRNA疫苗的患者出现了这种情况。</blockquote></p><p> Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p><p><blockquote>辉瑞和BioNTech正在合作研究和营销他们的新冠肺炎疫苗。疫苗的费用和利润由辉瑞和BioNTech平分。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158325931","content_text":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.\n\nBioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.\nThe WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.\nThere is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.\nBioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.\nThe conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.\nPfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1235,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}